上市生物制药公司 Acurx Pharmaceuticals 计划购买价值 100 万美元的比特币

Acurx Pharmaceuticals 是一家生物制药公司，开发用于治疗难以治疗的细菌感染的新型抗生素，该公司计划购买高达 100 万美元的比特币

Biopharmaceutical company Acurx Pharmaceuticals (NASDAQ:ACXP) is set to purchase up to $1 million in Bitcoin (CRYPTO: BTC) to hold the apex cryptocurrency as a “treasury reserve asset” on its balance sheet.

生物制药公司 Acurx Pharmaceuticals（纳斯达克股票代码：ACXP）计划购买最多 100 万美元的比特币（CRYPTO：BTC），以将顶级加密货币作为其资产负债表上的“国库储备资产”。

The board-approved strategy will see the New York-headquartered company leverage Bitcoin’s characteristics, which will provide a “functional store of value,” the company said in a press release on Saturday.

该公司在周六的新闻稿中表示，董事会批准的战略将使这家总部位于纽约的公司利用比特币的特性，这将提供“功能性的价值存储”。

“As demand for Bitcoin grows, and so does its acceptance as a major and primary asset class, we believe that Bitcoin will serve as a strong treasury reserve asset for cash not needed over the next 12 to 18 months,” said David P. Luci, Acurx Pharmaceuticals president and chief executive.

David P. Luci 表示：“随着对比特币的需求不断增长，以及它作为主要资产类别的接受度不断提高，我们相信比特币将成为未来 12 至 18 个月内不需要的现金的强大国库储备资产。” ，Acurx Pharmaceuticals 总裁兼首席执行官。

“With the recent approval of Bitcoin ETFs and the growing support from government agencies and institutional investors, it is a great addition to our treasury strategy.”

“随着最近比特币 ETF 的批准以及政府机构和机构投资者日益增长的支持，这是对我们财务策略的重要补充。”

The biopharmaceutical company’s move into Bitcoin comes as several companies are showing interest in the cryptocurrency. Earlier this year, Block Inc (NYSE:SQ) said it will allow users of its Cash App to send Bitcoin payments to friends and family members via email.

这家生物制药公司进军比特币之际，多家公司对加密货币表现出了兴趣。今年早些时候，Block Inc（纽约证券交易所股票代码：SQ）表示，将允许其 Cash App 用户通过电子邮件向朋友和家人发送比特币付款。

Also Read: 5 Things To Know Before The Market Opens Monday

另请阅读：周一开市前需要了解的 5 件事

Acurx Pharmaceuticals, founded in 2017, is a late-stage biopharmaceutical company that develops novel antibiotics targeting difficult-to-treat bacterial infections, particularly Gram-positive pathogens.

Acurx Pharmaceuticals 成立于 2017 年，是一家后期生物制药公司，开发针对难以治疗的细菌感染（特别是革兰氏阳性病原体）的新型抗生素。

The company is focused on advancing its lead product candidate, Ibezapolstat, through late-stage clinical development and regulatory approval.

该公司致力于通过后期临床开发和监管批准来推进其主要候选产品 Ibezapolstat。

Acurx Pharmaceuticals began trading on Nasdaq in 2021. Following the latest news, Acurx shares rose 6.6%, trading at $1.78 in pre-market trading, according to data from Nasdaq.

Acurx Pharmaceuticals 于 2021 年开始在纳斯达克交易。根据纳斯达克的数据，最新消息发布后，Acurx 股价上涨 6.6%，盘前交易价格为 1.78 美元。